Sign in
XENE Stock Price, Chart, Stats & News
Xenon Pharmaceuticals Inc.
Save
4.31B
Market cap
–
Current P/E
–
Forward P/E
XENE chart
1M
3M
1Y
5Y
Loading chart...
Fundamentals
Gross margin | -943.96% |
Operating margin | -4974.27% |
Pretax margin | -4598.59% |
Net margin | -4612.13% |
Effective tax rate | -0.29% |
ROA | -35.24% |
ROE | -55.81% |
D/E | 0.01x |
Interest coverage ratio | – |
XENE valuation
P/E | – |
P/S | 573.47x |
P/B | 7.42x |
P/CF | -15.47x |
P/FCF | -15.37x |
P/OCF | -15.47x |
PEG | 1.03x |
EV multiple | -12.50x |
About
Xenon Pharmaceuticals Inc. is a clinical-stage biopharmaceutical company dedicated to discovering and advancing innovative treatments for individuals living with neurological disorders. The company operates primarily from its headquarters in Burnaby, Canada. Its robust clinical pipeline showcases several promising candidates: XEN496, an activator of Kv7 potassium channels, is currently in Phase III clinical trials for KCNQ2 developmental and epileptic encephalopathy.
Similar securities
Based on sector and market capitalization
Report issue